ArticleFrontiers in pharmacology2022
Assessing the Consequences of External Reference Pricing for Global Access to Medicines and Innovation: Economic Analysis and Policy Implications.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- The impact of annual price revision based on external reference pricing on medicines between 2012 and 2023.Health economics review · 2026Article
- Collective international action to increase access to costly drugs: pooled procurement and equity based tiered pricing.BMJ (Clinical research ed.) · 2025Article
- Counting the savings: impact of Georgia's drug policy interventions on households.International journal for equity in health · 2025Article
- Stakeholder engagement and pharmaceutical pricing regulation: a qualitative inquiry.Journal of pharmaceutical policy and practice · 2025Article
- Drivers of innovation value: simulation for new drug pricing evaluation based on system dynamics modelling.Frontiers in pharmacology · 2025Article
- Artificial Intelligence to Automate Health Economic Modelling: A Case Study to Evaluate the Potential Application of Large Language Models.PharmacoEconomics - open · 2024Article
- Negotiating public-health intellectual property licensing agreements to increase access to health technologies: an insider's story.BMJ global health · 2023Review
- An Industry Survey on Unmet Needs in South Korea's New Drug Listing System.Therapeutic innovation & regulatory science · 2023Article
- Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU.Frontiers in public health · 2023Review
- How does external reference pricing work in developing countries: evidence from Iran.Frontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.